Last month PYC indicated that a FDA Regulatory Submission for FIH studies, (covering PKD), would be filed late in December. Based on PYC's track record, I am very confident this milestone will be met sometime in the next two weeks.
PYC have already provided an ASX Investor Presentation announcement with lots of information covering PKD, this is truly exciting stuff for all concerned. The coming regulatory submission announcement will likely solidify that we are indeed on track, and potentially be another shining example of PYC's ability to consistently deliver progressively on their clinical objectives.
In regard to PYC's SP, I hold space for the idea that the current retracement may be close to completion based on the above and my humble knowledge of Technical Analysis. Using post consolidation numbers, PYC has already exceeded a 50% Fibonacci retracement level and is close to the 61.8% mark, which puts it into a zone where traders may be looking for potential reversal... and for the uptrend to kick back in??
PYC Price at posting:
$1.41 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)